Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 7/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AHCY | P23526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22020877 | 0.94 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22666442 | 0.92 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22666249 | 0.91 | PI4KA (0.74) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21372144 | 0.89 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22142993 | 0.87 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21090693 | 0.85 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL23692926 | 0.83 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL25768221 | 0.83 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL26639075 | 0.83 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL18659819 | 0.83 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| US-11021511-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | PI4KA 2356/4885PI4K2B 2404/4885PI4K2A 2526/4885 |
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | STING1, TLR9, IFNAR1 | PI4KA 1252/4885PI4K2B 1656/4885PI4K2A 1470/4885 |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PI4KA 2386/4885PI4K2B 2341/4885PI4K2A 2482/4885 |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PI4KA 2378/4885PI4K2B 2290/4885PI4K2A 2437/4885 |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | PI4KA 2127/4885PI4K2B 2225/4885PI4K2A 2155/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | PI4KA 2127/4885PI4K2B 2225/4885PI4K2A 2155/4885 |
| US-11021511-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, MAVS | PI4KA 2390/4885PI4K2B 1643/4885PI4K2A 1854/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | PI4KA 1930/4885PI4K2B 2372/4885PI4K2A 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.